The Current Ratio as of September 2024 (TTM) for Xilio Therapeutics, Inc. (XLO) is 2.02

According to Xilio Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.02. This represents a change of -26.82% compared to the average of 2.76 of the last 4 quarters.

Xilio Therapeutics, Inc. (XLO) Historical Current Ratio (quarterly & annually)

How has XLO Current Ratio performed in the past?

The mean historical Current Ratio of Xilio Therapeutics, Inc. over the last ten years is 7.10. The current 2.02 Current Ratio has changed 2.74% with respect to the historical average. Over the past ten years (40 quarters), XLO's Current Ratio was at its highest in in the December 2021 quarter at 15.85. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Xilio Therapeutics, Inc. (XLO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Xilio Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xilio Therapeutics, Inc. (XLO) Average Current Ratio

How has XLO Current Ratio performed in the past?

The current Current Ratio of Xilio Therapeutics, Inc. (XLO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Xilio Therapeutics, Inc. (XLO) Current Ratio vs. Peers

How is XLO’s Current Ratio compared to its peers?

Xilio Therapeutics, Inc.’s Current Ratio is less than Connect Biopharma Holdings Limited (4.99), less than Tyra Biosciences, Inc. (36.46), less than RAPT Therapeutics, Inc. (8.14), less than Mineralys Therapeutics, Inc. (11.20), less than Edgewise Therapeutics, Inc. (0), less than Ikena Oncology, Inc. (30.24), less than Design Therapeutics, Inc. (18.22), less than Eliem Therapeutics, Inc. (41.42), less than Anebulo Pharmaceuticals, Inc. (60.41), less than AN2 Therapeutics, Inc. (5.32), less than Aerovate Therapeutics, Inc. (10.61), less than Adagene Inc. (6.51), less than Molecular Partners AG (2.50), less than MediciNova, Inc. (14.58), less than Champions Oncology, Inc. (18.24), greater than Cyteir Therapeutics, Inc. (0.69), less than null (21.89),

Build a custom stock screener for Xilio Therapeutics, Inc. (XLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xilio Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xilio Therapeutics, Inc. (XLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xilio Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.